News | August 25, 2025
GSK forays into oncology in India with Jemperli and Zejula
The company is bringing precision therapies for gynaecological cancers
The company is bringing precision therapies for gynaecological cancers
Dawnzera demonstrated significant and sustained HAE attack rate reduction and long-term disease control
The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study
The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities
Rocket will also collaborate with investigators to implement an immunomodulatory regimen more closely reflecting that administered in the Phase 1 pediatric cohort
NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity
The AI system was tested on digital slides from breast, colon, stomach, and esophageal cancer cases
This acquisition expands HGM's healthcare platform capabilities in revenue cycle management
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
According to IQVIA sales data for the 12-month period ending June 2025, the Mycamine for Injection, 50 mg/vial and 100 mg/vial market achieved annual sales of approximately $60.7 million
Subscribe To Our Newsletter & Stay Updated
